Kevin C Adam
Associate, White & Case LLP
Kevin Adam is a litigation associate in White & Case’s New York and Boston offices and a member of the Global Competition Group. His practice focuses on complex litigation in the areas of antitrust, intellectual property, and commercial disputes. Kevin represents several leading global pharmaceutical companies in class-action litigation matters at the cutting edge of antitrust and intellectual property, including AGGRENOX, ASACOL, BOTOX, DORYX, and NAMENDA. He also has experience in antitrust, intellectual property, and commercial matters in the agricultural, aviation, banking, casino, college admissions, health insurance, oil & gas, and technology industries.
Kevin regularly speaks and writes about antitrust, intellectual property, and technology. He has published a number of articles in those areas and is a co-author of a book on class actions titled "Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation."
Kevin also has an extensive pro bono practice, with a particular focus on criminal appellate work and civil-rights litigation. He has represented criminal defendants and wrongfully convicted individuals in New York's Appellate Division, the New York Court of Appeals, and federal court in Massachusetts. In 2016, Kevin successfully vacated a criminal conviction obtained by the New York Attorney General's Office in New York's First Department.